Becton Dickinson has posted four consecutive earnings beats and trades at 10.9 times forward earnings with exceptional free cash flow conversion at 398% of net income, offering roughly 8% upside to the analyst consensus target; a momentum gate failure with the stock below its 200-day moving average and a sole-source supplier concentration risk are the primary obstacles to a more constructive stance.
Thesis pillars
- Consistent Earnings Execution Four Streak↓Deteriorating
- Attractive Valuation Forward Multiple→Stable
- Exceptional Free Cash Flow Conversion↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Becton, Dickinson and Company (BDX) Stock Analysis
Healthcare · Medical Instruments & Supplies
Sell if holding. Analyst target reached at $183.40 — A.R:R is negative (-0.6) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Supplier: sole sourced.
Becton, Dickinson and Company develops, manufactures, and sells medical devices, laboratory equipment, and diagnostic products through three segments — BD Medical, BD Life Sciences, and BD Interventional — serving hospitals, clinics, laboratories, and pharmaceutical companies... Read more
Sell if holding. Analyst target reached at $183.40 — A.R:R is negative (-0.6) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Supplier: sole sourced. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.2/10, moderate confidence.
Passes 5/8 gates (positive momentum, clean insider activity, earnings proximity 82d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and news legal. Suitability: moderate.
About Becton, Dickinson and Company
About Becton, Dickinson and Company
Becton, Dickinson and Company's three segments — BD Medical, BD Life Sciences, and BD Interventional — supply medical devices, diagnostic instruments, and vascular specialty products to hospitals, laboratories, and pharmaceutical companies in over 20 countries. The company completed the $3.914 billion acquisition of Edwards Lifesciences' Critical Care product group in September 2024, and in July 2025 signed a definitive agreement to separate its Biosciences and Diagnostic Solutions businesses in a Reverse Morris Trust with Waters Corporation, expected to close around Q1 2026 calendar year, with BD to receive approximately $4 billion in cash.
BD Medical generates revenue through catheter systems, IV infusion pumps including the BD Alaris platform, prefillable drug delivery systems for pharmaceutical manufacturers, and hemodynamic monitoring systems acquired from Edwards Lifesciences in 2024. BD Life Sciences sells automated diagnostic instruments, reagent systems, blood collection platforms, and cell analysis tools to hospitals, blood banks, and academic researchers. BD Interventional offers single-use vascular, urological, and surgical specialty devices to hospitals and ambulatory surgery centers, primarily through direct sales and independent distribution channels. The company operates in a market where group purchasing organizations and health system consolidation have intensified pricing pressure, and large medical device companies as well as technology companies are expanding into the healthcare sector.
Show full overview
BD's U.S. infusion pump business operates under an FDA Consent Decree entered in 2007 and amended in 2009, covering all infusion pumps manufactured by CareFusion 303, Inc., which BD acquired in 2015. In December 2021, the FDA issued a Non-Compliance Letter noting certain corrective actions were inadequate; in November 2024, BD received a separate FDA Warning Letter specific to the BD Pyxis dispensing quality management system — a product line outside the Consent Decree's scope. CareFusion 303, Inc. is required to maintain an independent expert auditor through 2025, and the FDA's review of 2024 Form 483 observations on the Infusion quality management system remains ongoing.
See also: Healthcare · Medical Instruments & Supplies
From Becton, Dickinson and Company's most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-08-15Recent Developments — Becton, Dickinson and Company
Latest news
- NEWS Becton Dickinson (NYSE:BDX) Gains Fresh Operating Focus - Kalkine Media — Kalkine Media positive
- NEWS Becton Dickinson (NYSE:BDX) Gains Fresh Operating Focus - kalkinemedia.com — kalkinemedia.com positive
- NEWS Becton Dickinson (BDX) On Its Brazil Semaglutide Push And The Valuation Narrative - Yahoo Finance — Yahoo Finance neutral
- NEWS Becton Dickinson (BDX) On Its Brazil Semaglutide Push And The Valuation Narrative - finance.yahoo.com — finance.yahoo.com positive
- NEWS BDX Looks 11.6% Undervalued on GF Value™ with a Sustainable 2.52% Dividend Yield - GuruFocus — GuruFocus positive
Generated 2026-08-15T09:37:15Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSuppliersole sourced10-K Item 1: 'there are situations where raw materials and components may only be obtained from one supplier, which are referred to as sole sourced'
- MEDIUMGeographicinternational operations10-K Item 1A: 'A substantial amount of our sales come from our operations outside the U.S.'
Material Events(8-K, last 90d)
- 2026-04-09Item 5.02MEDIUMRichard E. Byrd, Executive Vice President and President of the Interventional segment, officer change effective April 6, 2026. Body truncated; no reason cited or successor named.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $183.40 — A.R:R is negative (-0.6) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Supplier: sole sourced. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $173.78. Score 5.2/10, moderate confidence.
Take-profit target: $210.91 (-8.9% upside). Prior stop was $173.78. Stop-loss: $173.78.
Concentration risk — Supplier: sole sourced; Analyst target reached - limited upside remaining; Near 52-week high (2.1% away).
Becton, Dickinson and Company trades at a P/E of 31.8 (forward 13.7). TrendMatrix value score: 6.3/10. Verdict: Sell.
21 analysts cover BDX with a consensus score of 3.7/5. Average price target: $192.
What does Becton, Dickinson and Company do?Becton, Dickinson and Company develops, manufactures, and sells medical devices, laboratory equipment, and diagnostic...
Becton, Dickinson and Company develops, manufactures, and sells medical devices, laboratory equipment, and diagnostic products through three segments — BD Medical, BD Life Sciences, and BD Interventional — serving hospitals, clinics, laboratories, and pharmaceutical companies globally. Revenue flows from device sales, reagent systems, and service contracts distributed directly and through independent channels across more than 20 countries of manufacturing.